Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CSCC_ASC is an allogeneic adipose-derived mesenchymal stem cell (ASC) therapy developed by the Copenhagen Stem Cell Centre (CSCC) at Rigshospitalet. These cells are harvested from the adipose tissue of healthy adult donors and expanded for therapeutic use. CSCC_ASC exerts its effects through immunomodulatory, anti-inflammatory, and regenerative mechanisms, including the secretion of paracrine factors that reduce tissue fibrosis and promote healing. The therapy is primarily investigated for the treatment of radiation-induced hyposalivation and xerostomia in head and neck cancer survivors, Sjögren's syndrome-related dry eye and dry mouth, and severe respiratory complications associated with COVID-19 and lung transplantation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CSCC_ASC.